Related Experiment Video
Updated: Jun 6, 2026
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Booster dose vaccination for preventing hepatitis B.
Jalal Poorolajal1, Mahmood Mahmoodi, Aliakbar Haghdoost
1Department of Epidemiology and Biostatistics, Research Centre for Health Sciences, Faculty of Health, Hamadan University of Medical Sciences (UMSHA), Shahid Fahmideh Avenue, Hamadan, Hamadan, Iran, 6517838695.
The Cochrane Database of Systematic Reviews
|November 12, 2010
Summary
Booster hepatitis B vaccinations may extend protection, but no clinical trials currently exist to confirm their benefits or harms. Further research is needed to establish future hepatitis B booster policies.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Antibody levels against hepatitis B surface antigen (HBs) decrease over time post-vaccination.
- The long-term protection duration of hepatitis B (HB) vaccines remains uncertain.
- Assessing the anamnestic immune response to booster doses offers an indirect measure of vaccine efficacy.
Purpose of the Study:
- To evaluate the benefits and harms of hepatitis B (HB) booster vaccinations in preventing HB infection.
- To determine the effectiveness of booster doses in maintaining immunity against hepatitis B.
Main Methods:
- A systematic review of randomized clinical trials was conducted.
- Searches included major databases (Cochrane, MEDLINE, EMBASE) up to May 2010.
- Inclusion criteria focused on trials assessing anamnestic response to HB vaccine boosters at least five years post-primary vaccination.
Main Results:
- No eligible randomized clinical trials were identified that met the review's inclusion criteria.
- The review could not find direct evidence from clinical trials on the efficacy or safety of HB vaccine boosters.
Conclusions:
- There is a lack of randomized clinical trials investigating the role of hepatitis B vaccine boosters.
- Further research, specifically randomized clinical trials, is essential to guide future policies on hepatitis B booster vaccination schedules.
- Evidence-based recommendations for hepatitis B booster policies cannot be formulated without robust clinical trial data.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:51Vaccinations
Overview
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:20Chickenpox
Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...